N1VO34
Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B · BMFBOVESPA:N1VO34
26.75 BRL0.4900 +1.87%
Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B (BMFBOVESPA:N1VO34) last traded at 26.75 BRL, up 1.87% on the day. Over the past year the stock is down 21.11%. Its 52-week range is 22.90 to 42.43. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open26.59
Day range26.59 – 27.22
52-week range22.90 – 42.43
Volume136.26 K
Average volume (10 days)33.31 K
Market cap (USD)175.64 B
P/E1.29
EPS (TTM) (USD)3.99
Dividend yield4.40%
Beta (1 year)−0.3277
Revenue (TTM) (USD)50.21 B
Employees68.79 K
Performance
+7.65%1 week
+8.26%1 month
−10.92%3 months
+3.16%6 months
−24.26%Year to date
−21.11%1 year
Technical rating
Buy
Daily summary of 11 oscillators and 15 moving averages. See every indicator
Latest headlines
- Weekly Recap: Wegovy scripts 265k+ and injunction denied in Eli Lilly ad suitTradingView · 02 Nov 2026
- Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up NextStocktwits · 02 Nov 2026
- Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week — Barrons.comDow Jones Newswires · 01 Nov 2026
- Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
- Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on CancerBenzinga · 29 Oct 2026
- Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
- Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED)Benzinga · 28 Oct 2026
- LLY Vs NVO: Lilly’s Retatrutide Beats Novo’s Ozempic In Head-To-Head Trial — Retatrutide More Than Doubles Weight LossStocktwits · 28 Oct 2026
Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.